Ending Brain Disease
Starts
Here
Transformative preclinical evaluation of novel therapeutics that will lead to a world without brain disease.
Proin ac nisl et
sapien porttitor
The TRanslational Initiative to DE-risk NeuroTherapeutics (TRIDENT) is revolutionizing preclinical trials for the treatments of neurodegenerative diseases with a $24 million grant from the Government of Canada's New Frontiers In Research Program.
Funded by a $24M grant through the federal New Frontiers in Research Program, the TRanslational Initiative to ​DE-risk NeuroTherapeutics (TRIDENT) offers a transformative approach to preclinical evaluation of neurotherapeutics, dramatically improving their odds of success in clinical trials for the benefit of millions of patients. ​ ​
By de-risking the development of new drugs, ​TRIDENT will reinvigorate public and private investment in therapeutics for these debilitating conditions and accelerate ​the discovery of a cure to end brain disease.
Maecenas consectetur massa ac velit
Quisque nulla felis, pretium non tincidunt sit amet, semper eget lectus. Vestibulum vel dictum turpis. Mauris malesuada nisi in risus convallis tristique. Praesent commodo risus nulla. Vivamus fringilla sed orci ac auctor. In ut ultrices lorem.
Sed in aliquam
Funder port
Etiam maximus sodales justo ut iaculis. Ut vitae quam in massa pulvinar venenatis eget non lectus. Nam varius eros vel euismod posuere.
Headquartered at
in collaboration with
